Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Independent association of a 17q21 variant with exacerbations in type 2-low adult asthma.
The journal of allergy and clinical immunology. Global·2025
Same author
Dynamic property of central airway walls assessed by computed tomography: correlation with asthma pathophysiology.
The Journal of asthma : official journal of the Association for the Care of Asthma·2025
Same author
Impact of adding pethidine on disinhibition during bronchoscopy with midazolam: a propensity score matching analysis.
Respiratory investigation·2023
Related Experiment Video
Updated: May 27, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
[Novel therapeutics for COPD].
Yuma Hoshino1, Shigeo Muro, Michiaki Mishima
1Department of Respiratory Medicine, Kyoto University Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 12, 2011
Summary
Novel therapies targeting molecular mechanisms are crucial for managing chronic obstructive pulmonary disease (COPD). Research focuses on anti-inflammatory agents to combat persistent inflammation and lung cell loss in COPD patients.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Pharmacology
Context:
- Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder primarily linked to cigarette smoking.
- Key pathological processes include inflammation, oxidative stress, apoptosis, and protease activity, leading to lung matrix degradation and cell loss.
- COPD-related inflammation often persists post-smoking cessation and shows resistance to glucocorticoids, necessitating novel therapeutic strategies.
Purpose:
- To review emerging molecularly targeted agents for COPD treatment.
- To discuss novel anti-inflammatory agents aimed at preventing disease progression.
- To highlight therapeutic targets including signal transduction molecules, cytokines, chemokines, adhesion molecules, oxidative stress mediators, and proteases.
Summary:
- This review examines novel therapeutic agents for COPD, focusing on molecular targets.
- It discusses agents targeting signal transduction pathways, inflammatory mediators (cytokines, chemokines), adhesion molecules, oxidative stress, and proteases.
- The development of these targeted therapies is driven by a clearer understanding of COPD's underlying molecular mechanisms.
Impact:
- Advances in understanding COPD pathogenesis have spurred the development of targeted therapeutics.
- Novel agents offer potential for more effective management of persistent inflammation and disease progression in COPD.
- Targeted therapies represent a promising frontier for improving clinical outcomes in patients with chronic obstructive pulmonary disease.